Please login to the form below

Not currently logged in
Email:
Password:

Galafold

This page shows the latest Galafold news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Orchard Therapeutics raises 150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval

Daily Brief: Orchard Therapeutics raises 150m, Astellas swoops for early-stage gene company, Amicus gets FDA Fabry approval

Amicus’s Galafold gains FDA approval, set to rival Fabrayzme. Amicus Therapeutics has received FDA approval for Galafold, the first oral therapy for the rare Fabry disease. ... Galafold is a long-term treatment for adult patients with specific genetic

Latest news

  • Orphan drugs dominate UK Prix Galien shortlist, medtech debuts Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

    This year, the judges concluded that just two entrants were worthy of being shortlisted for the Innovative Product Award; Sanofi (Dupixent) and Amicus (Galafold). ... Seven companies have been shortlisted for the Orphan Product Award; Amicus (Galafold),

  • Amicus Therapeutics launches Fabry treatment Galafold in Italy Amicus Therapeutics launches Fabry treatment Galafold in Italy

    Amicus Therapeutics launches Fabry treatment Galafold in Italy. Follows publication of Ministry of Health's reimbursement guidelines. ... US biotech Amicus Therapeutics has launched its new Fabry disease treatment Galafold (migalastat) in Italy after

  • Amicus gets NICE green light for Fabry drug Amicus gets NICE green light for Fabry drug

    Amicus gets NICE green light for Fabry drug. Oral therapy alternative Galafold approved for routine NHS use. ... Fabry disease affects an estimated 855 people in England, of whom around 140 would be eligible for treatment with Galafold, according to

  • SMC approves Opdivo combo as first-line skin cancer treatment SMC approves Opdivo combo as first-line skin cancer treatment

    SMC approves Opdivo combo as first-line skin cancer treatment. Also backs Gilead’ s Epclusa, Baxalta’ s Oncaspar, AZ’ s Lynparza and Amicus’ Galafold. ... Amicus Therapeutics' Galafold (migalastat) has also received the go-ahead, and has been

  • NICE backs Amicus Therapeutics’ Galafold NICE backs Amicus Therapeutics’ Galafold

    The UK's NICE has recommended the use of Galafold (migalastat) on the NHS for the treatment of Fabry disease in draft Highly Specialised Technologies guidance. ... Fabry disease affects an estimated 855 people in England, of whom around 140 would be

More from news
Approximately 5 fully matching, plus 2 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics